FDA has granted Orphan Drug Designation to BI 1819479 for the potential treatment of idiopathic pulmonary fibrosis.
Boehringer Ingelheim announced that FDA has granted Orphan Drug Designation to BI 1819479 for the potential treatment of idiopathic pulmonary fibrosis (IPF). BI 1819479 is an investigational compound that may address pulmonary fibrosis—a scarring of the lung tissue that negatively…